EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM): A prospective observational study on incidence of arrhythmias

Peter Magnusson, Stellan Mörner, Peter Magnusson, Stellan Mörner

Abstract

Background: Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease associated with arrhythmias. Non-sustained ventricular tachycardia (NSVT) is a risk factor for sudden cardiac death and part of the current risk stratification. Furthermore, atrial fibrillation (AF), which increases the risk of stroke, is believed to be common in HCM patients. Routine ambulatory monitoring captures the rhythm only periodically over 24-48 h; thus, the true burden of arrhythmia is unknown. The insertable cardiac monitor (ICM) should help determine a more realistic arrhythmia assessment in HCM patients.

Objective: The purpose of this study was to ascertain the incidence of NSVT, AF, and bradycardia in unselected HCM patients by the use of an ICM.

Methods: Thirty adults, mean age 49.9 ± 12.3 years, 25 (83.3%) males were implanted with a Confirm Rx ICM. The monitoring application was installed on the patient's smartphone, which allowed for patient activation in case of symptoms. The ICM was programmed as follows: ventricular tachycardia (VT) ≥ 160 beats per minute (bpm) for ≥8 intervals, AF ≥ 2 min of duration, and bradycardia ≤ 40 bpm or pause ≥ 3.0 s.

Results: The mean calculated 5-year risk was 2.3%, and 29/30 of the patients had a risk <4%. During follow-up, AF was found in nine patients (30.0%). At least one episode of NSVT was detected in seven patients (23.3%). In 13 patients (43.3%), sinoatrial block/sinus arrest/sinus bradycardia were seen. No arrhythmia was detected in nine patients (30.0%).

Conclusion: In this first prospective study using an ICM, the arrhythmia burden in HCM patients yielded 30.0% AF and 23.3% NSVT.

Trial registration: ClinicalTrials.gov NCT03259113.

Keywords: arrhythmia; atrial fibrillation; hypertrophic cardiomyopathy; insertable cardiac monitor; non-sustained ventricular tachycardia.

Conflict of interest statement

Peter Magnusson received speaker's fee/grants from Abbott, Alnylam, AstraZeneca, Bayer, Boehringer‐Ingelheim, Lilly, MSD, Novo Nordisk, Octopus Medical, Pfizer, and Zoll. Stellan Mörner has no disclosures.

© 2020 The Authors. Journal of Cardiovascular Electrophysiology published by Wiley Periodicals LLC.

Figures

Figure 1
Figure 1
Atrial fibrillation detected by Confirm Rx
Figure 2
Figure 2
Non‐sustained ventricular tachycardia detected by Confirm Rx

References

    1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270‐276.
    1. Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100:465‐472.
    1. Elliott PM, Anastasakis A, Borger MA, et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;2014:2733‐2779.
    1. Wang N, Xie A, Tjahjono R, et al. Implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: an updated systematic review and meta‐analysis of outcomes and complications. Ann Cardiothorac Surg. 2017;6:298‐306.
    1. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124:2761‐2796.
    1. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas‐Lado M, McKenna WJ. Non‐sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873‐879.
    1. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:697‐704.
    1. Schinkel AFL, Vriesendorp PA, Sijbrands EJG, Jordaens LJLM, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta‐analysis. Circ Heart Fail. 2012;5:552‐559.
    1. O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk‐SCD). Eur Heart J. 2014;35:2010‐2020.
    1. O'Mahony C, Jichi F, Ommen SR, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE‐HCM). Circulation. 2018;137:1015‐1023.
    1. Kirchhof P, Benussi S, Kotecha D. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;38:2893‐2962.
    1. Nölker G, Mayer J, Boldt LH, et al. Performance of an implantable cardiac monitor to detect atrial fibrillation: results of the DETECT AF Study. J Cardiovasc Electrophysiol. 2016;27:1403‐1410.
    1. Magnusson P, Mörner S. EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)—rationale and design: a prospective observational study on incidence of arrhythmias in Sweden. BMJ Open. 2017;7:e019541.
    1. Force T, Bonow R, Houser S, et al. Research priorities in hypertrophic cardiomyopathy. Report of a Working Group of the National Heart, Lung, and Blood Institute. Circulation. 2010;122:1130‐1133.
    1. Gorenek B, Bax J, Boriani, et al. ESC Scientific Document Group. Device‐detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2017;19(9):1556‐1578.
    1. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120‐129.
    1. Rowin EJ, Hausvater A, Link MS, et al. Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2017;136:2420‐2436.
    1. Choi YJ, Choi EK, Han KD, et al. Temporal trends of the prevalence and incidence of atrial fibrillation and stroke among Asian patients with hypertrophic cardiomyopathy: a nationwide population‐based study. Int J Cardiol. 2018;273:130‐135.
    1. Brignole M, Auricchio A, Baron‐Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA). Europace. 2013;(15):1070‐118.
    1. Weidemann F, Maier S, Stefan Störk S. Usefulness of an implantable loop recorder to detect clinically relevant arrhythmias in patients with advanced Fabry cardiomyopathy. Am J Cardiol. 2016;118:264‐274.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅